TY - JOUR
T1 - European Sero-Epidemiology Network 2
T2 - Standardisation of immunoassay results for pertussis requires homogeneity in the antigenic preparations
AU - Giammanco, Anna
AU - Nardone, Antony
AU - Pebody, Richard
AU - Kafatos, George
AU - Andrews, Nick
AU - Chiarini, Alfredo
AU - Taormina, Susanna
AU - de Ory, Fernando
AU - Prosenc, Katarina
AU - Krize, Bohumir
AU - Hallander, Hans
AU - Ljungman, Margaretha
AU - Marva, Esther
AU - Tsakris, Athanassios
AU - O'Flanagan, Darina
AU - Schneider, François
AU - Griskevicius, Algirdas
AU - Vranckx, Robert
AU - Karacs, Ildiko
N1 - Funding Information:
This work was funded by a grant from the European Commission (contract number QLK2-CT-2000-00542); a further source of funding was the ISCIII MPY1075/01 (Spain). Authors thank for the assistance: Salvatore Distefano (Italy), M.E. Guisasola (Spain), Alenka Kraigher (Slovenia) and Marina Maixnerova (Czek Republik).
PY - 2008/8/18
Y1 - 2008/8/18
N2 - A standardisation process, already developed during the earlier European Sero-Epidemiology Network (ESEN) project, was employed with a more robust algorithm to harmonise results of pertussis serological assays performed in 12 European and non-European countries. Initially, results from each country's own assay were compared with those obtained at the reference laboratory by means of an in-house pertussis toxin (PT)-based ELISA: seven countries used in-house or commercial PT-ELISAs; the other countries used assays based on Bordetella pertussis whole cell extracts (WCE) (three countries) or on combined PT-FHA (filamentous haemagglutinin) antigenic preparations (two countries). The WCE assays, although admitted for diagnostic purposes, confirmed their low correlation with the PT-ELISAs and their results could not be used for standardisation; the PT-FHA ELISAs gave results that were suitable for standardisation in one country but unsatisfactory in the other; the use of purified PT in serological assays confirmed its better reliability than other preparations and all PT-ELISAs results could be calibrated against those of the reference centre. In the standardisation process two high-titre cut-offs indicative of likelihood of recent infection (from within 4 weeks of disease onset up to 1 year after) were included for evaluations as they are suggested to be more useful, for the sero-epidemiological assays of immunity to pertussis, than the cut-off of protection, commonly employed, but still not defined for pertussis. Providing PT-ELISAs are used, standardisation of pertussis assay results is always possible and, when standardisation is performed, evaluation and comparison of the impact of different interventions can be also allowed, by measuring at the distribution of high antibody titres in the populations.
AB - A standardisation process, already developed during the earlier European Sero-Epidemiology Network (ESEN) project, was employed with a more robust algorithm to harmonise results of pertussis serological assays performed in 12 European and non-European countries. Initially, results from each country's own assay were compared with those obtained at the reference laboratory by means of an in-house pertussis toxin (PT)-based ELISA: seven countries used in-house or commercial PT-ELISAs; the other countries used assays based on Bordetella pertussis whole cell extracts (WCE) (three countries) or on combined PT-FHA (filamentous haemagglutinin) antigenic preparations (two countries). The WCE assays, although admitted for diagnostic purposes, confirmed their low correlation with the PT-ELISAs and their results could not be used for standardisation; the PT-FHA ELISAs gave results that were suitable for standardisation in one country but unsatisfactory in the other; the use of purified PT in serological assays confirmed its better reliability than other preparations and all PT-ELISAs results could be calibrated against those of the reference centre. In the standardisation process two high-titre cut-offs indicative of likelihood of recent infection (from within 4 weeks of disease onset up to 1 year after) were included for evaluations as they are suggested to be more useful, for the sero-epidemiological assays of immunity to pertussis, than the cut-off of protection, commonly employed, but still not defined for pertussis. Providing PT-ELISAs are used, standardisation of pertussis assay results is always possible and, when standardisation is performed, evaluation and comparison of the impact of different interventions can be also allowed, by measuring at the distribution of high antibody titres in the populations.
KW - ESEN (European Sero-Epidemiology Network)
KW - Immunoassay standardisation
KW - Pertussis antigenic preparations
KW - Pertussis sero-epidemiology
UR - https://www.scopus.com/pages/publications/48449088237
U2 - 10.1016/j.vaccine.2008.06.051
DO - 10.1016/j.vaccine.2008.06.051
M3 - Article
C2 - 18602434
AN - SCOPUS:48449088237
SN - 0264-410X
VL - 26
SP - 4486
EP - 4493
JO - Vaccine
JF - Vaccine
IS - 35
ER -